rs1014971
This is a intergenic variant variant.
▶GWAS Catalog Trait Associations (1)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
GWAS Catalog Trait Associations (1)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
urinary bladder carcinoma
▶Research that mentions this SNP (2)
▶Genetic polymorphisms on 8q24.1 and 4p16.3 are not linked with urothelial carcinoma of the bladder in contrast to their association with aggressive upper urinary tract tumoursAssociationN=492David R. Yates et al.(2013)· World Journal of Urology
This case-control study of 231 bladder urothelial carcinoma (UC) patients and 261 benign controls found that rs9642880[T] and rs798766[T] variants increase bladder-UC risk (OR=1.72, p=0.028 and OR=1.84, p=0.01 respectively), but unlike upper tract UC, these variants are not associated with disease aggressiveness (grade or stage). The findings highlight distinct genetic differences between bladder-UC and upper urinary tract urothelial carcinoma.
▶The association between bladder cancer and a single nucleotide polymorphism (rs2854744) in the insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) geneAssociationN=486Mohammad Reza Safarinejad et al.(2011)· Archives of Toxicology
This Iranian case-control study examined the association between the IGFBP-3 A-202C polymorphism (rs2854744) and bladder cancer risk in 162 cancer patients and 324 controls. The study found that the AA genotype was protective against bladder cancer (OR=0.48, 95% CI 0.24-0.64, P=0.001) while the AC genotype increased risk (OR=1.76, 95% CI 1.27-2.84, P=0.038). The protective effect of the AA genotype was more pronounced in advanced bladder cancers, with no AA genotype carriers having high-grade tumors.
This variant is in our database but has no known associations or PRS memberships yet.
Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…